Enzymotec Ltd. announced that the company has been granted two patents, one by the United States Patent Office and the second by the Chinese Patent and Trademark Office. The U.S. patent covers certain substitute milk fat compositions and the processes related to their production as it pertains to infant nutrition. The Chinese patent covers the use of INFAT in promoting the development of beneficial gut flora in subjects at risk of developing an imbalance and in reducing the frequency and duration of infant crying.

INFAT is a clinically-proven fat ingredient 3that closely resembles the composition, structure and nutritional value of natural fat found in human breast milk that is necessary for proper infant health, development and comfort. Previously published clinical data demonstrated that infants fed with formula containing INFAT developed a more beneficiary gut bacteria profile compared to a control formula. Beneficial gut bacteria promote good health and development and an ability to prevent infections.

Additional clinical data indicated that babies nourished with infant formula containing INFAT cry less and for a shorter duration in comparison to babies fed with infant formula not containing INFAT.